Member Info for DugWalker

Chris Hoy on BBC news with a woman from Prostate Cancer UK. Discussed the shortcomings of PSA and the ongoing 'Transfom' project. According to Prostate Cancer UK the Transform project 'will identify the best diagnostic options for a national screening programme.

Participation in Transform would have given OBD access to a medically/statistically approved trial cohort at a scale ensuring medical validation of our test. As mentioned on the news the budget for Transform is £42 million and a share of that would have secured the company's finances for the foreseeable.

Our BoD has yet to provide a satisfactory explanation as to why participation was not secured, even though Burrow's once said our participation was 'critical'. Was it ineptitude or negligence. If the latter was it intentional?

With the lights about to go off in a matter of weeks it is outrageous that they have not offered shareholders the courtesy of an update on the promised 'strategic review'. Their treatment of the poor buggers that pay their salaries is nothing short of contemptuous.

..and they have increased their holding yet again

Obviously confident about the takeover.

A lifestyle company yesterday and a lifestyle company today.

Apologies Alf. Missed that. Too early in the morning.

When a company is valued at £4 million but has a salary bill that must be close to half of that value, I would see a low ball takeover bid as more realistic option to keep the lights on, than a partnership. They are now fundamentally a company that is diluting shareholder value month on month to pay salaries. Anyone with an interest in OBD would want to stop that immediately.

What on earth leads you to the conclusion that they have found a partner? Have I missed something here? A low ball takeover of a company valued at £4 million seems more likely.

Hard to see 'news' that they cannot make the oral presentations content and are relegated to a poster presentation at a conference as a positive. In fact the continued spending on attendance seems an extravagance with money about to runout in a fee weeks.

Surely the real indication of meaningful interest would be an announcement of a strategic partnership or a buyer of IP that would avoid a placing or issuance of CLN's. The lack of an update of the 'strategic review' is concerning.

...keep increasing their holding. I wonder if they know something? 😉

Morning Kong.

The lack of news meaningful news is in itself worth discussing. Remember a cash raise is one of the few realistic options they have to finance the company next year and they need to act on that within weeks.

It is very much in their interest to ensure a positive newsflow to try and get the SP up ahead of a placing so the lack of an update on their

"strategic review" does not bode well.

I'm concerned that with XMas looming they don't have time to negotiate a sell off of IP so it seems we are weeks away from insolvency.

News on the survival strategy review is badly needed for this to see any meaningful increase in SP.

I wish. As of now

Vol bought 43,500, Bought value £ n/a.

News on their survi

Have a hunch investors will be the bigger winners here.

Transform Prostate was an opportunity to have full clinical validation at scale and with a medically approved cohort, funded by government and charity. The fact this BoD were blissfully unaware of the opportunity until it was too late tells you everything you need to know about them. Let's hope they demonstrate competence when negotiating the sell off of the family silver, but I won't be holding my breath in anticipation.

Less than 10 weeks before the money runs out, so I thought they might have done shareholders the courtesy of an update on the promised strategic review. Have they identified buyers for any of the tests under development? Have negotiations started? What about the 'hiving off' of the US business?

Surely they must now have a preferred route to avoiding further damage to shareholders?

Https://www.share-talk.com/rns-hotlist-with-zak-mir-gex-arv-gmet-gdlf-jlp-msmn-pxen/

9p takes us back to the pre-placing price range so he's obviously not accounting for the Viura wells which have potential to push price significantly north of that.

@Swazers.

Well done on your speedy ammendment to include comment on Viura. I believe many have overlooked the significance of the recent Viura deal with Heyco. Notably Heyco has taken a stake in PXEN so the company now has a partner with huge cash reserves anexperience of operating in Spain. Heyco conducted due diligence on PXEN's Spanish assets and seem to like what they saw.

El Romeral permits lan̈d and a takeover looks a distinct possibility but it will be Heyco rather than Hankhawk.

Viura is transformational so omitting it from an investment review article is careless. Perhaps Swazers can quickly review his conclusions and put out a modified article?

....given the upward trend in the TTF gas price the results should be encouraging. Po Valley Shares (ASX) were up 8% overnight on above average volumes.

Our operating partner (Po Valley Energy) of our assets in Italy, should be announcing Q3 results any day now. Given the upward tren